New stroke drug could give patients up to 24 hours to seek treatment
NCT ID NCT07201688
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a drug called rhTNK-tPA (Mingfule) in people with acute ischemic stroke who can be treated 4.5 to 24 hours after symptoms start. The study plans to enroll 890 participants and will compare the drug to a placebo. The goal is to see if the drug helps patients recover better, as measured by their ability to perform daily activities independently.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rhTNK-tPA (a clot-busting drug)
- What this could lead to
- If successful, this could allow more stroke patients to receive clot-busting treatment up to 24 hours after symptoms start, potentially reducing disability.
- What could go wrong
- This is an early Phase 3 trial, so results are not yet proven. There is a risk of bleeding in the brain, a known side effect of clot-busters.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Puyang Oilfield General Hospital
RECRUITINGPuyang, Henan, 457001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?